ライフサイエンスコーパス: vulvovaginal

1 d FGTCs (total n = 28 [2.0%]; cervical = 22, vulvovaginal = 4, and anal/rectal = 2) than HIV-negative

2 e women (total n = 32 [0.6%]; cervical = 24, vulvovaginal = 5, and anal/rectal = 5) (log rank P < .00

3 The IRs for vulvovaginal and anal cancers were also higher in WLWH.

4 Information about vulvovaginal and perianal condylomata acuminata and intr

5 Vulvovaginal and perianal condylomata acuminata or intra

6 s for sexual-related concerns other than for vulvovaginal atrophy in female cancer survivors.

7 The treatment of vulvovaginal atrophy includes administration of estrogen

8 ts with GSM symptoms, including dyspareunia, vulvovaginal atrophy, and recurrent urinary tract infect

9 n, uniformly had clinical evidence of severe vulvovaginal atrophy, dyspareunia (median pain score, 8

10 promising as a therapeutic option to improve vulvovaginal atrophy.

11 ll tolerated with no secondary cases of VVC; vulvovaginal burning was the most common adverse event (

12 ), gonorrhea (HR, 1.6; 95% CI, 1.1-2.2), and vulvovaginal candidiasis (HR, 1.5; 95% CI, 1.3-1.8).

13 Recurrent vulvovaginal candidiasis (RVVC) affects up to 8% of wome

14 Studies from women with recurrent vulvovaginal candidiasis (RVVC) and from an animal model

15 not associated with development of recurrent vulvovaginal candidiasis (RVVC) in women.

16 The estimated prevalence of recurrent vulvovaginal candidiasis (RVVC) was 2,739/100,000.

17 e and susceptibility to recurrent idiopathic vulvovaginal candidiasis (RVVC) was investigated.

18 and moderate sensitivity and specificity for vulvovaginal candidiasis (sensitivity 64.4%, specificity

19 The diagnosis of vulvovaginal candidiasis (VVC) by the Affirm and Candida

20 Vulvovaginal candidiasis (VVC) caused by Candida albican

21 Vulvovaginal candidiasis (VVC) caused by Candida albican

22 Vulvovaginal candidiasis (VVC) caused by the commensal o

23 da causes an estimated half-billion cases of vulvovaginal candidiasis (VVC) every year.

24 sseminated candidiasis (HDC) and episodes of vulvovaginal candidiasis (VVC) in humans, we found evide

25 Vulvovaginal candidiasis (VVC) is a common cause of vulv

26 Vulvovaginal candidiasis (VVC) is a common mucosal infec

27 Vulvovaginal candidiasis (VVC) is a high-incidence disea

28 Vulvovaginal candidiasis (VVC) is an insidious infection

29 Vulvovaginal candidiasis (VVC) is an opportunistic mucos

30 Acute vulvovaginal candidiasis (VVC) is common among women, bu

31 Current treatment of vulvovaginal candidiasis (VVC) is largely limited to azo

32 Candida test using a reference standard for vulvovaginal candidiasis (VVC) of yeast culture plus exc

33 Bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC) present serious reproduct

34 Acute and recurrent vulvovaginal candidiasis (VVC) remains a significant pro

35 bacterial vaginosis (BV) and/or symptomatic vulvovaginal candidiasis (VVC), 195 (18.5%) had one or m

36 s the causative agent of acute and recurrent vulvovaginal candidiasis (VVC), a common mucosal infecti

37 rial vaginosis (BV), 25 acquired symptomatic vulvovaginal candidiasis (VVC), and 7 acquired vaginal t

38 re assessed for bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC), and tested for M. homini

39 s vaginitis due to bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and Trichomonas vaginali

40 mmon, diagnosis of bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and Trichomonas vaginali

41 ion with lactobacilli may reduce the risk of vulvovaginal candidiasis (VVC), but supporting data are

42 Vulvovaginal candidiasis (VVC), caused by Candida albica

43 Vulvovaginal candidiasis (VVC), caused by Candida specie

44 Vulvovaginal candidiasis (VVC), caused primarily by Cand

45 opharyngeal candidiasis (OPC), as opposed to vulvovaginal candidiasis (VVC), is a common opportunisti

46 Vulvovaginal candidiasis (VVC), mainly caused by Candida

47 ections, including bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), or Trichomonas vaginalis

48 ctions, notably bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC), particularly in the sett

49 t common infection caused by Candida spp. is vulvovaginal candidiasis (VVC), which affects >70% of wo

50 st commonly as oropharyngeal candidiasis and vulvovaginal candidiasis (VVC).

51 = 2) with OPC in 1 patient, whereas isolated vulvovaginal candidiasis (VVC; n = 3) was not.

52 Vulvovaginal candidiasis affects approximately 75% of wo

53 anslocation, nor do we implicate the gene in vulvovaginal candidiasis among mice in pseudoestrus.

54 oth clinical studies of women with recurrent vulvovaginal candidiasis and a murine model of experimen

55 24 premenopausal women with acute recurrent vulvovaginal candidiasis and from 21 healthy asymptomati

56 eatment-emergent adverse events (TEAEs) were vulvovaginal candidiasis and nausea (each 2.7%).

57 In contrast, vulvovaginal candidiasis has a much weaker association w

58 p-based vaccine, protected against recurrent vulvovaginal candidiasis in women.

59 The risks of GUD and vulvovaginal candidiasis increased with progressive leve

60 ch higher numbers of bacterial vaginosis and vulvovaginal candidiasis infections.

61 is sensitivity 61.6%, specificity 46.0%; and vulvovaginal candidiasis sensitivity 74.6%, specificity

62 women with non-antibiotic-induced recurrent vulvovaginal candidiasis suffering from acute Candida va

63 e randomly assigned 387 women with recurrent vulvovaginal candidiasis to receive treatment with fluco

64 b-), the relative risk of chronic recurring vulvovaginal candidiasis was 2.41-4.39, depending on the

65 Vulvovaginal candidiasis was treated presumptively.

66 hoeae, T vaginalis, bacterial vaginosis, and vulvovaginal candidiasis were the gold standard, and all

67 infection, Trichomonas vaginalis infection, vulvovaginal candidiasis, and bacterial vaginosis) in HI

68 diarrhea, C. difficile infection, vaginitis/vulvovaginal candidiasis, and pneumonia.

69 ted to testing for bacterial vaginosis (BV), vulvovaginal candidiasis, and trichomoniasis.

70 Vulvovaginal candidiasis, caused primarily by Candida al

71 chlamydia, bacterial vaginosis, trichomonas, vulvovaginal candidiasis, pelvic inflammatory disease, g

72 e antifungal susceptibility of yeast causing vulvovaginal candidiasis, since cultures are rarely perf

73 ypeptides in both bacterial vaginosis and in vulvovaginal candidiasis, suggesting that the abnormalit

74 Unlike in vulvovaginal candidiasis, the neutrophil attractant chem

75 In mice with vulvovaginal candidiasis, topical dextran sulfate admini

76 lbicans, in mice models of oropharyngeal and vulvovaginal candidiasis.

77 conazole, are now available for treatment of vulvovaginal candidiasis.

78 of oral ibrexafungerp in patients with acute vulvovaginal candidiasis.

79 18.1% for bacterial vaginosis, and 8.6% for vulvovaginal candidiasis.

80 o colonization and immunopathogenesis during vulvovaginal candidiasis.

81 protection in oral infection but exacerbate vulvovaginal candidiasis.

82 ed to fluid from healthy women or women with vulvovaginal candidiasis.

83 March 2001 from 429 patients with suspected vulvovaginal candidiasis.

84 reduce the rate of recurrence of symptomatic vulvovaginal candidiasis.

85 zole was effective in preventing symptomatic vulvovaginal candidiasis.

86 be effective for the management of recurrent vulvovaginal candidiasis.

87 trial, NDV-3A protected women from recurrent vulvovaginal candidiasis.

88 acy to fluconazole in the treatment of acute vulvovaginal candidiasis.

89 pain; non-Clostridioides difficile diarrhea; vulvovaginal candidiasis/vaginitis).

90 Despite therapeutic advances, vulvovaginal candidosis remains a common problem worldwi

91 The most common yeast infection is recurrent vulvovaginal candidosis, affecting 12,300-81,600 women a

92 in both overdiagnosis and underdiagnosis of vulvovaginal candidosis.

93 t-centered measure of adverse experiences in vulvovaginal care was developed.

94 patients before their first appointment at a vulvovaginal disorder referral clinic from August 2023 t

95 65% of women, resulting in symptoms such as vulvovaginal dryness, discomfort, and dysuria, which sig

96 that presented as the oral component of the vulvovaginal-gingival syndrome.

97 s appears to reduce the risk of cervical and vulvovaginal HPV infection.

98 patients with recurrent infections, oral and vulvovaginal isolates were identical, in 35% they were h

99 ginal candidiasis (VVC) is a common cause of vulvovaginal itching and discharge.

100 lesions were reflective of sexual practices: vulvovaginal lesions predominated in cis women and non-b

101 o (1%) of 341 HIV-1-negative women developed vulvovaginal or perianal lesions, resulting in an incide

102 biopsychosocial, trauma-informed approach to vulvovaginal pain and continued development of validated

103 We investigated vaginal size, vulvovaginal pathology and the presence of the main huma

104 valuation, has been described anecdotally in vulvovaginal patient care, but has not been quantified.

105 ltaneously cultured from the oral cavity and vulvovaginal region of healthy individuals.

106 Cervical and vulvovaginal samples for HPV DNA testing and Papanicolao

107 questionnaire was completed and cervical and vulvovaginal samples were collected to detect HPV DNA.

108 with a clinical cure (complete resolution of vulvovaginal signs and symptoms [VSS] = 0) at test-of-cu

109 Patients with vulvovaginal signs and symptoms score >=7 were randomize

110 with a clinical cure (complete resolution of vulvovaginal signs and symptoms) at the test-of-cure vis

111 necologic examinations included cervical and vulvovaginal specimen collection for Pap and HPV DNA tes

112 rtner was identical or highly related to the vulvovaginal strain.

113 that included HPV genotyping of cervical and vulvovaginal swab specimens and collection of colposcopy

114 In community settings, both vulvovaginal-swab and first-catch urine specimens from w

115 ting Chlamydia trachomatis in self-collected vulvovaginal-swab and first-catch urine specimens from w

116 We tested 2,745 paired vulvovaginal-swab and urine specimens by PCR (Roche Coba

117 I], 93.1 to 99.2%) of infected patients with vulvovaginal-swab specimens and 91.8% (86.1 to 95.7%) wi

118 We tested 2,749 vulvovaginal-swab specimens with both a nucleic acid amp

119 tivity of an amplified enzyme immunoassay on vulvovaginal-swab specimens.

120 and rectum, plus first catch urine (MSM) and vulvovaginal swabs (females), for NG/CT detection.

121 and rectum, plus first catch urine (MSM) and vulvovaginal swabs (females), for NG/CT detection.

122 tum, plus first-catch urine (FCU) in MSM and vulvovaginal swabs (VVS) in females, for NG and CT detec

123 tum, plus first catch urine (FCU) in MSM and vulvovaginal swabs (VVS) in females, for NG and CT detec

124 and behavioral information and cervical and vulvovaginal swabs for HPV DNA assay were obtained at 4-

125 Participants had at least one GSM vulvovaginal symptom in the month prior (dryness, itchin

126 indicates the most severe symptoms) and the Vulvovaginal Symptom Questionnaire (VSQ; range, 0-20; 0

127 Women with vulvovaginal symptoms (aOR, 2.70; 95% CI, 2.45-2.97) and

128 musculoskeletal adverse events (MSAEs), and vulvovaginal symptoms (VVSs) in postmenopausal patients

129 inhibitors were recruited, among whom 25 had vulvovaginal symptoms and 25 had no vulvovaginal symptom

130 s Gardnerella was significantly increased in vulvovaginal symptoms group with no differences in bacte

131 Vulvovaginal symptoms were monitored and scored for each

132 n cancer populations (ie, low sexual desire, vulvovaginal symptoms, negative body image, and sexual p

133 with a low estrogenic state with and without vulvovaginal symptoms.

134 d with aromatase inhibitors with and without vulvovaginal symptoms.

135 e hormonal agents are effective remedies for vulvovaginal symptoms.

136 m 25 had vulvovaginal symptoms and 25 had no vulvovaginal symptoms.